Abaloparatide Before Total Knee Arthroplasty

April 3, 2025 updated by: University of Wisconsin, Madison

An Open-Label Phase 2 Study of Abaloparatide to Mitigate Distal Femoral Bone Loss Following Total Knee Arthroplasty

The investigator hypothesizes that treating osteoporotic patients with abaloparatide prior to and after total knee arthroplasty will significantly reduce the amount of bone loss.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

In primary unilateral total knee arthroplasty patients, The investigator will examine the effect of daily abaloparatide therapy in clinical osteoporotic patients beginning 3 months pre-op and continued for a total of 15 months. This will be compared to osteopenic patients receiving no therapy as well as previously published values in untreated osteoporotic patients 12 months following Total Knee Arthroplasty (TKA).

Study Type

Interventional

Enrollment (Actual)

58

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Wisconsin
      • Madison, Wisconsin, United States, 53705
        • University of Wisconsin

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

55 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria

  1. Post-menopausal women and men age ge ≥ 55 years and scheduled to undergo primary TKA at the University of Wisconsin Total Joint Program.
  2. Osteoporosis, i.e., BMD T-score (using female reference data) ≤ -2.5 at the lumbar spine, femoral neck OR total hip or ≤ -1.1 with Vertebral Fracture Assessment confirmed vertebral fracture or history of low-trauma nonvertebral fracture in the past 5 years OR osteopenia, BMD T-score (using female reference data) -1.1 to -2.4 at the lumbar spine, femoral neck or total hip and no prior low-trauma fracture.
  3. Serum calcium (albumin-corrected), serum creatinine and Parathyroid(PTH) values all within the normal range and 25(OH)D > 10 ng/mL.
  4. Willing to supplement with daily calcium and/or vitamin D3 at protocol specified doses.
  5. Able to provide written informed consent.

Exclusion Criteria

  1. Unevaluable distal femur BMD due to hardware or other artifacts.
  2. History of bone disorders (e.g., Paget's disease) other than osteoporosis.
  3. History of prior external beam or implant radiation therapy involving the skeleton other than radioiodine.
  4. History of chronic or recurrent renal, hepatic, pulmonary, allergic, cardiovascular, gastrointestinal, endocrine, central nervous system, hematologic or metabolic diseases, or immunologic, emotional and/or psychiatric disturbances that, in opinion of the principal investigator, would compromise study data validity.
  5. History of Cushing's disease, growth hormone deficiency or excess, hyperthyroidism, hypo- or hyperparathyroidism or malabsorptive syndromes within the past year.
  6. History of significantly impaired renal function (serum creatinine >2.0 mg/dL. If the serum creatinine is > 1.5 and ≤ 2.0 mg/dL, the calculated creatinine clearance (Cockcroft-Gault) must be ≥ 37 mL/min.
  7. History of nephrolithiasis or urolithiasis within the past five years.
  8. History of cancer in prior 5 years (basal cell or squamous skin cancer is permissible).
  9. History of osteosarcoma at any time.
  10. Patients known to be positive for Hepatitis B, Hepatitis C, HIV-1 or HIV-2.
  11. Known hypersensitivity to any of the test materials or related compounds.
  12. Prior treatment with PTH- or PTHrP-derived drugs, (ABL, teriparatide or PTH (1-84)).
  13. Prior treatment with intravenous bisphosphonates at any time or oral bisphosphonates within the past three years. Patients who had received a short course of oral bisphosphonate therapy (3 months or less) may be enrolled as long as the treatment occurred 6 or more months prior to enrollment.
  14. Treatment with fluoride or strontium in the past five years or prior treatment with bone-acting investigational agents at any time.
  15. Treatment with calcitonin the past 6 months or denosumab in the past 18 months.
  16. Treatment with anticonvulsants affecting vitamin D metabolism (phenobarbital, phenytoin, carbamazepine or primidone) or chronic heparin within the prior 6 months.
  17. Treatment with anabolic steroids or calcineurin inhibitors (cyclosporin, tacrolimus)
  18. Daily treatment with oral, intranasal or inhaled glucocorticoids in the prior 12 months.
  19. Exposure to any investigational drug within 12 months.
  20. Consumption of > 2 alcoholic drinks per day or use of illegal drugs within 12 months of screening.
  21. Not suitable for study participation due to other reasons at the investigators discretion.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Treatment group

Those with clinical osteoporosis who elect ABL treatment.

ABL therapy will begin 3 months pre-TKA and continue for a total of 18 months. ABL will be administered by injection pen with dose of 80 mcg SC qDay.
Drug: Abaloparatide
18 month ABL treatment
Other Names:
  • Tymlos
No Intervention: Comparator group
Those with clinical osteopenia who receive no treatment.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Distal femoral Bone mineral density (BMD) at the 25% regions of interest (ROIs)
Time Frame: Baseline and 18 months
Bone mineral density change at the 25% ROI of the surgical leg
Baseline and 18 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Distal femoral BMD at the 15% and 60 %ROI
Time Frame: Baseline and 18 months
Bone mineral density change at the 15% and 60% ROI of the surgical leg
Baseline and 18 months
Change in Femur cortical thickness at the 15%, 25% and 60% femur ROIs
Time Frame: Baseline and 18 months
Cortical thickness change at the 15% and 60% ROI of the surgical leg
Baseline and 18 months
TBS assessment by TRIP at the 15%, 25% and 60% femur ROIs
Time Frame: 18 months
Trabecular bone score (TBS) assessment by Texture Research Investigation (Platform (TRIP) software change at the 15%, 25% and 60% femur ROIs (TBS >1.350 is normal; TBS between 1.200 and 1.350 is indicative of partially degraded microarchitecture; and TBS<1.200 equals degraded microarchitecture)
18 months
Knee injury & Osteoarthritis Outcome Score (KOOS) JR
Time Frame: 18 months
Patient reported knee function score. The KOOS, JR was developed from the original long version of the Knee injury and Osteoarthritis Outcome Score (KOOS) survey using Rasch analysis. The KOOS, JR contains 7 items from the original KOOS survey. Items are coded from 0 to 4, none to extreme respectively. KOOS, JR is scored by summing the raw response (range 0-28) and then converting it to an interval score (0-100). The interval score ranges from 0 to 100 where 0 represents total knee disability and 100 represents perfect knee health.
18 months
Change in Veterans RAND 12 (VR-12) Question Health Survey score
Time Frame: Baseline and 18 months
12 Item Health Survey using patient's self assessment of their perspective of their health and ability to do daily functions. Scores are derived using an algorithm that is referenced to a metric centered at 50.0 where a zero score indicates the lowest level of health and 100 indicates the highest level of health.
Baseline and 18 months
Forgotten Joint Survey(FJS) score
Time Frame: 18 months

FJS-12 consists of 12 questions and is scored using a 5-point response format with the raw scores transformed onto a 0- to 100-point scale.

High scores indicate good outcome, that is, a high degree of forgetting the joint in everyday life (forgotten joint phenomenon).
18 months
Change in body composition using bioelectrical impedance analysis of lean mass
Time Frame: Baseline and 18 months
Change in body composition using bioelectrical impedance analysis of lean mass.
Baseline and 18 months
Change in body composition using bioelectrical impedance analysis of skeletal mass.
Time Frame: Baseline and 18 months
Change in body composition using bioelectrical impedance analysis of skeletal mass.
Baseline and 18 months
Change in body composition using bioelectrical impedance analysis of fat mass.
Time Frame: Baseline and 18 months
Change in body composition using bioelectrical impedance analysis of fat mass.
Baseline and 18 months
TKA complications: Number of participants needed revision surgery
Time Frame: 18 months
TKA complications: Number of participants needed revision surgery
18 months
TKA complications: Number of participants had fracture
Time Frame: 18 months
TKA complications: Number of participants had fracture
18 months
Precision Error on Knee Bone Density Measurement
Time Frame: up to 15 months
Precision assessment in the field of bone densitometry is the process whereby the ability of the instrument and the technologist to reproduce similar results, given no real biologic change, is tested. The mathematical result of precision assessment is called the precision error. To achieve statistical power, the investigators will take duplicate knee bone density measurements on 30 participants at either their 6 month or 15 month visit. The standard deviation for each participant is calculated, then the root mean square standard deviation for the group is calculated.
up to 15 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Wisconsin, Madison

Collaborators

Radius Health, Inc.

Investigators

  • Principal Investigator: Neil Binkley, MD, University of Wisconsin, Madison

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 10, 2020

Primary Completion (Actual)

April 3, 2025

Study Completion (Actual)

April 3, 2025

Study Registration Dates

First Submitted

October 29, 2019

First Submitted That Met QC Criteria

November 15, 2019

First Posted (Actual)

November 18, 2019

Study Record Updates

Last Update Posted (Actual)

April 4, 2025

Last Update Submitted That Met QC Criteria

April 3, 2025

Last Verified

April 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2019-0685
  • A534255 (Other Identifier: UW- Madison)
  • SMPH/MEDICINE/MEDICINE*G (Other Identifier: UW Madison)
  • Protocol Version 3/22/2021 (Other Identifier: UW Madison)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Osteoporosis

Clinical Trials on Abaloparatide

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Philippines

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe